Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Status:
Completed
Trial end date:
2017-06-13
Target enrollment:
Participant gender:
Summary
The objectives of this single-arm, open-label trial are to assess the efficacy and safety of
afatinib as second line treatment for patients with locally advanced or metastatic non-small
cell lung cancer (NSCLC) harbouring a common EGFR mutation who have failed first-line
platinum-based chemotherapy and to demonstrate that the efficacy and safety are comparable to
the results seen in previous trials.